Hostname: page-component-586b7cd67f-g8jcs Total loading time: 0 Render date: 2024-11-29T10:20:33.806Z Has data issue: false hasContentIssue false
  • English
  • Français

Effect of ciprofloxacin on the pharmacokinetics of intravenous lidocaine

Published online by Cambridge University Press:  15 September 2005

M. H. Isohanni ,
J. Ahonen ,
P. J. Neuvonen  and
K. T. Olkkola
M. H. Isohanni
Affiliation:
Diacor Hospital, Department of Anaesthesia, Finland University of Helsinki, Department of Clinical Pharmacology, Helsinki, Finland
J. Ahonen
Affiliation:
University of Helsinki, Department of Anaesthesiology and Intensive Care Medicine, Helsinki, Finland
P. J. Neuvonen
Affiliation:
University of Helsinki, Department of Clinical Pharmacology, Helsinki, Finland
K. T. Olkkola
Affiliation:
University of Turku, Department of Anaesthesiology and Intensive Care, Turku, Finland
Get access

Extract

Summary

Background and objective: Recent studies have suggested that cytochrome P-450 isoenzyme 1A2 has an important role in lidocaine biotransformation. We have studied the effect of a cytochrome P-450 1A2 inhibitor, ciprofloxacin, on the pharmacokinetics of lidocaine. Methods: In a randomized, double-blinded, cross-over study, nine healthy volunteers ingested for 2.5 days 500 mg oral ciprofloxacin or placebo twice daily. On day 3, they received a single dose of 1.5 mg kg−1 lidocaine intravenously over 60 min. Plasma concentrations of lidocaine, 3-hydroxylidocaine and monoethylglycinexylidide were determined for 11 h after the start of the lidocaine infusion. Results: Ciprofloxacin increased the mean peak concentration and area under plasma concentration–time curve of lidocaine by 12% (range −6 to +46%; P < 0.05) and 26% (8–59%; P < 0.01), respectively. The mean plasma clearance of lidocaine was decreased by ciprofloxacin by 22% (7–38%; P < 0.01). Ciprofloxacin decreased the area under the plasma concentration–time curve of monoethylglycinexylidide by 21% (P < 0.01) and that of 3-hydroxylidocaine by 14% (P < 0.01). Conclusion: The plasma decay of intravenously administered lidocaine is modestly delayed by concomitantly administered ciprofloxacin. Ciprofloxacin may increase the systemic toxicity of lidocaine.

Keywords

ANAESTHETICS, LOCAL, lidocainePHARMACOKINETICS, lidocaineCYTOCHROME P-450 ENZYME SYSTEM, cytochrome P-450 CYP1A2, antagonists and inhibitors
Type
Original Article
Information
European Journal of Anaesthesiology , Volume 22 , Issue 10 , October 2005 , pp. 795 - 799
Copyright
© 2005 European Society of Anaesthesiology

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Tucker GT, Mather LE. Clinical pharmacokinetics of local anaesthetics. Clin Pharmacokinet 1979; 4: 241–279.Google Scholar
Bargetzi MJ, Aoyama T, Gonzales FJ, Meyer UA. Lignocaine metabolism in human liver microsomes by P450IIIA4. Clin Pharmacol Ther 1989; 46: 521–527.Google Scholar
Wang J-S, Backman JT, Wen X, Taavitsainen P, Neuvonen PJ, Kivistö KT. Fluvoxamine is a more potent inhibitor of lidocaine metabolism than ketoconazole and erythromycin in vitro. Pharmacol Toxicol 1999; 85: 201–205.Google Scholar
Wang J-S, Backman JT, Taavitsainen P, Neuvonen PJ, Kivistö KT. Involvement of CYP1A2 and CYP3A4 in lidocaine N-deethylation and 3-hydroxylation in humans. Drug Metab Dispos 2000; 28: 959–965.Google Scholar
Olkkola KT, Isohanni MH, Hamunen K, Neuvonen PJ. Effect of erythromycin and fluvoxamine on the pharmacokinetics of intravenous lidocaine. Anesth Analg 2005; 100: 1352–1356.Google Scholar
Orlando R, Piccoli P, De Martin S, Padrini R, Floreani M, Palatini P. Cytochrome P450 1A2 is a major determinant of lidocaine metabolism in vivo: effects of liver function. Clin Pharmacol Ther 2004; 75: 80–88.Google Scholar
Davis R, Markham A, Balfour JA. Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy and tolerability. Drugs 1996; 51: 1019–1074.Google Scholar
Wijnands WJ, Vree TB, van Herwaarden CL. The influence of quinolone derivatives on theophylline clearance. Br J Clin Pharmacol 1986; 22: 677–683.Google Scholar
Batty KT, Davis TM, Ilett KF, Dusci LJ, Langton SR. The effect of ciprofloxacin on theophylline pharmacokinetics in healthy subjects. Br J Clin Pharmacol 1995; 39: 305–311.Google Scholar
Nicolau DP, Nightingale CH, Tessier PR et al. The effect of fleroxacin and ciprofloxacin on the pharmacokinetics of multiple dose caffeine. Drugs 1995; 49 (Suppl 2): 357–359.Google Scholar
Jokinen MJ, Olkkola KT, Ahonen J, Neuvonen PJ. Effect of ciprofloxacin on the pharmacokinetics of ropivacaine. Eur J Clin Pharmacol 2003; 58: 653–657.Google Scholar
Lorec A-M, Bruguerolle B, Attolini L, Roucoules X. Rapid simultaneous determination of lidocaine, bupivacaine and their two main metabolites using capillary gas–liquid chromatography with nitrogen–phosporus detector. Ther Drug Monit 1994; 16: 592–595, 21S–28S.Google Scholar
Demedts P, Wauters A, Franck F, Neels H. Simultaneous determination of lidocaine, bupivacaine and their two main metabolites using gas chromatography and a nitrogen– phosporus detector: selection of stationary phase and chromatographic conditions. Ther Drug Monit 1996; 18: 208–211.Google Scholar
Volmer DA, Mansoori B, Locke SJ. Study of 4-quinolone antibiotics in biological samples by short-column liquid chromatography coupled with electrospray ionization tandem mass spectrometry. Anal Chem 1997; 69: 4143–4155.Google Scholar
Keenaghan JB, Boyes RN. The tissue distribution, metabolism and excretion of lidocaine in rats, guinea pigs, dogs and man. J Pharmacol Exp Ther 1972; 180: 454–463.Google Scholar
Imaoka S, Enomoto K, Oda Y et al. Lidocaine metabolism by human cytochrome P-450s purified from hepatic microsomes: comparison of those with rat hepatic cytochrome P-450s. J Pharmacol Exp Ther 1990; 255: 1385–1391.Google Scholar
Isohanni MH, Neuvonen PJ, Palkama VJ, Olkkola KT. Effect of erythromycin and itraconazole on the pharmacokinetics of intravenous lignocaine. Eur J Clin Pharmacol 1998; 54: 561–565.Google Scholar
Bertz RJ, Granneman GR. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 1997; 32: 210–258.Google Scholar
Rygnestad T, Zahlsen K, Bergslien O, Dale O. Focus on mobilisation after lower abdominal surgery. A double-blind randomised comparison of epidural bupivacaine with morphine vs. lidocaine with morphine for postoperative analgesia. Acta Anaesthesiol Scand 1999; 43: 380–387.Google Scholar
Gianelli R, Von der Groeben JO, Spicavk AP, Harrison DS. Effect of lidocaine (xylocaine) on ventricular arrhythmias in patients with coronary heart disease. New Engl J Med 1967; 277: 1215–1219.Google Scholar
Benowitz NL, Meister W. Clinical pharmacokinetics of lignocaine. Clin Pharmacokinet 1978; 3: 177–201.Google Scholar
Jokinen MJ, Ahonen J, Neuvonen PJ, Olkkola KT. The effect of erythromycin, fluvoxamine, and their combination on the pharmacokinetics of ropivacaine. Anesth Analg 2000; 91: 1207–1212.Google Scholar